258 related articles for article (PubMed ID: 26878872)
1. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
[TBL] [Abstract][Full Text] [Related]
2. p63 protein expression in high risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
[TBL] [Abstract][Full Text] [Related]
3. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.
Hu WM; Jin JT; Wu CY; Lu JB; Zhang LH; Zeng J; Lin SX
Diagn Pathol; 2019 Nov; 14(1):128. PubMed ID: 31711519
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
7. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma-leg type, and is of the TAp63 isoform.
Robson A; Shukur Z; Ally M; Kluk J; Liu K; Pincus L; Sahni D; Sundram U; Subtil A; Karai L; Kempf W; Schieke S; Coates P
Histopathology; 2016 Jul; 69(1):11-9. PubMed ID: 26332336
[TBL] [Abstract][Full Text] [Related]
9. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
[TBL] [Abstract][Full Text] [Related]
10. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
11. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
13. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
14. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
17. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
[TBL] [Abstract][Full Text] [Related]
18. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of p53 and p63 in Diffuse Large B-Cell Lymphoma: A Single-Institution Experience.
Moreno JCA; Bahmad HF; Aljamal AA; Delgado R; Salami A; Guillot C; Castellano-Sánchez AA; Medina AM; Sriganeshan V
Curr Oncol; 2023 Jan; 30(2):1314-1331. PubMed ID: 36826063
[TBL] [Abstract][Full Text] [Related]
20. Expression of p63 in diffuse large B-cell lymphoma.
Hedvat CV; Teruya-Feldstein J; Puig P; Capodieci P; Dudas M; Pica N; Qin J; Cordon-Cardo C; Di Como CJ
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):237-42. PubMed ID: 16082248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
